Literature DB >> 10854097

Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia).

E Schollen1, S Kjaergaard, E Legius, M Schwartz, G Matthijs.   

Abstract

The R141H mutation in the PMM2 gene is the most frequent mutation in type Ia of the congenital disorders of glycosylation (formerly carbohydrate-deficient glycoprotein syndromes)(CDG-Ia). However, it has never been observed in the homozygous state. Homozygosity for this mutation is probably incompatible with life. In this study, we determined the frequency of R141H in two normal populations: in neonates of Dutch origin 1/79 were carriers, whilst in the Danish population, a carrier frequency of 1/60 was found. These figures are clearly in disequilibrium with the frequency of CDG-Ia that has been estimated at 1/80,000 to 1/40,000 in these populations. Haplotype analysis of 43 patients with the R141H mutation of different geographic origins indicated that the R141H is an old mutation in the Caucasian population. Based on the new data, the disease frequency has been calculated at 1/20,000 in these populations. It is concluded that the disease is probably underdiagnosed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854097     DOI: 10.1038/sj.ejhg.5200470

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  32 in total

Review 1.  New disorders in carbohydrate metabolism: congenital disorders of glycosylation and their impact on the endocrine system.

Authors:  Bradley S Miller; Hudson H Freeze
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

Review 2.  Antenatal manifestations of inborn errors of metabolism: biological diagnosis.

Authors:  Christine Vianey-Saban; Cécile Acquaviva; David Cheillan; Sophie Collardeau-Frachon; Laurent Guibaud; Cécile Pagan; Magali Pettazzoni; Monique Piraud; Antonin Lamazière; Roseline Froissart
Journal:  J Inherit Metab Dis       Date:  2016-07-08       Impact factor: 4.982

3.  Expanding the Spectrum of PMM2-CDG Phenotype.

Authors:  Sandrine Vuillaumier-Barrot; Bertrand Isidor; Thierry Dupré; Christiane Le Bizec; Albert David; Nathalie Seta
Journal:  JIMD Rep       Date:  2011-12-25

Review 4.  Congenital disorders of glycosylation.

Authors:  Irene J Chang; Miao He; Christina T Lam
Journal:  Ann Transl Med       Date:  2018-12

5.  High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency).

Authors:  S Grünewald; E Schollen; E Van Schaftingen; J Jaeken; G Matthijs
Journal:  Am J Hum Genet       Date:  2001-01-11       Impact factor: 11.025

6.  The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations.

Authors:  B Pérez; P Briones; D Quelhas; R Artuch; A I Vega; E Quintana; L Gort; M J Ecay; G Matthijs; M Ugarte; C Pérez-Cerdá
Journal:  JIMD Rep       Date:  2011-06-22

7.  Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.

Authors:  Vandana Sharma; Mie Ichikawa; Ping He; David A Scott; Yalda Bravo; Russell Dahl; Bobby G Ng; Nicholas D P Cosford; Hudson H Freeze
Journal:  J Biol Chem       Date:  2011-09-26       Impact factor: 5.157

Review 8.  Solving glycosylation disorders: fundamental approaches reveal complicated pathways.

Authors:  Hudson H Freeze; Jessica X Chong; Michael J Bamshad; Bobby G Ng
Journal:  Am J Hum Genet       Date:  2014-02-06       Impact factor: 11.025

9.  Clinical utility gene card for: Phosphomannomutase 2 deficiency.

Authors:  Jaak Jaeken; Dirk Lefeber; Gert Matthijs
Journal:  Eur J Hum Genet       Date:  2014-01-15       Impact factor: 4.246

10.  Involvement of the modifier gene of a human Mendelian disorder in a negative selection process.

Authors:  Isabelle Jéru; Hasmik Hayrapetyan; Philippe Duquesnoy; Emmanuelle Cochet; Jean-Louis Serre; Josué Feingold; Gilles Grateau; Tamara Sarkisian; Marc Jeanpierre; Serge Amselem
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.